Another myostatin program combusts, but Acceleron has plenty in the pipeline – Endpoints News

Myostatin inhibitors — engineered to build muscle and improve mobility in patients — theoretically make sense for use in patients with muscle-wasting diseases. But the field is littered with failure — and so it was hardly surprising when Acceleron, which years ago scrapped a myostatin program it had partnered with Shire, disclosed another flopped myostatin drug on Monday.

Acceleron’s drug, ACE-083, was being tested in a mid-stage study in patients with Charcot-Marie-Tooth disease (CMT), a group of inherited disorders that cause nerve damage and are characterized by smaller, weaker muscles.

Click here to read full article

Font Resize